Perioperative Chemoradiotherapy May Improve Survival in Urethral Carcinoma

Share this content:

the Cancer Therapy Advisor take:

Patients who received neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy for cT3 and/or cN+ primary urethral carcinoma (PUC) appeared to demonstrate improved survival compared with those who underwent upfront surgery with or without adjuvant chemotherapy, a recent study published online in the journal Annals of Oncology has shown.

For the study, researchers sought to assess the effect of perioperative chemo(radio)therapy) in patients with advanced PUC. Researchers identified 124 patients who were diagnosed and underwent surgery for PUC between 1993 and 2012.

Results showed that the objective response rate was 25% and 33% for neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy, respectively.

For patients who achieved an objective response to neoadjuvant treatment, the 3-year overall survival was 100% for those who received neoadjuvant chemotherapy and 58.3% for those who received neoadjuvant chemoradiotherapy (P = 0.30).

In the locally advanced subset of patients, the 3-year overall survival was 100% for those who received neodjuvant chemotherapy, 100% for those who received neoadjuvant chemotherapy, 50% for those who underwent surgery alone, and 20% for those who underwent surgery plus adjuvant chemotherapy (P = 0.016).

The study demonstrated a significant association between neoadjuvant treatment and improved 3-year relapse-free survival (P = 0.022) and overall survival (P = 0.022). 

In patients with completely resected high-risk stage 3 melanoma, adjuvant ipilimumab significantly i
Patients who received neoadjuvant chemotherapy for primary urethral carcinoma appeared to demonstrate improved survival.
To investigate the impact of perioperative chemo(radio)therapy in advanced primary urethral carcinoma (PUC).
READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters